Novel siRNA Therapeutic Demonstrates Significant Fat Loss and Remarkable Lean Body Mass Preservation, and Promises Superior Adherence
NEW YORK, Jan. 10, 2025 /CNW/ - Canary Cure Therapeutics, a pioneer in next-generation RNA therapeutics development, today announced breakthrough preclinical results for its lead candidate CCT-217, addressing two critical challenges in current obesity treatments: muscle mass loss and poor medication adherence.
Read more at newswire.caThis article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.